Lauren MBA - ImmunoGen Senior Officer
| IMGNDelisted Stock | USD 31.23 0.01 0.03% |
Executive
Lauren MBA is Senior Officer of ImmunoGen
| Age | 45 |
| Phone | 781 895 0600 |
| Web | https://www.immunogen.com |
ImmunoGen Management Efficiency
The company has return on total asset (ROA) of (0.0849) % which means that it has lost $0.0849 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1988) %, meaning that it created substantial loss on money invested by shareholders. ImmunoGen's management efficiency ratios could be used to measure how well ImmunoGen manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 15.24 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. ImmunoGen has a current ratio of 4.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist ImmunoGen until it has trouble settling it off, either with new capital or with free cash flow. So, ImmunoGen's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ImmunoGen sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ImmunoGen to invest in growth at high rates of return. When we think about ImmunoGen's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Suba Krishnan | Mereo BioPharma Group | 59 | |
| Alex Howarth | Madrigal Pharmaceuticals | 55 | |
| Roman Necina | Hookipa Pharma | 56 | |
| Matthew Beck | Hookipa Pharma | N/A | |
| John SullivanBolyai | Hepion Pharmaceuticals | 76 | |
| Diana Chung | Terns Pharmaceuticals | N/A | |
| Mark Winderlich | Hookipa Pharma | N/A | |
| Gregory Conn | PDS Biotechnology Corp | 69 | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| David Ege | Seres Therapeutics | 49 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Daniel Trepanier | Hepion Pharmaceuticals | N/A | |
| Bo Kara | Mereo BioPharma Group | N/A | |
| Mark MBA | X4 Pharmaceuticals | 60 | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| Catriona Yale | Akero Therapeutics | 52 | |
| RPh Young | Seres Therapeutics | 57 | |
| Gayle Gironda | Inozyme PharmaInc | N/A | |
| Sanjay Zaveri | PDS Biotechnology Corp | N/A | |
| Edward Chiang | Madrigal Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0849 |
ImmunoGen Leadership Team
Elected by the shareholders, the ImmunoGen's board of directors comprises two types of representatives: ImmunoGen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ImmunoGen. The board's role is to monitor ImmunoGen's management team and ensure that shareholders' interests are well served. ImmunoGen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ImmunoGen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel JD, VP Officer | ||
| Susan Altschuller, VP CFO | ||
| MMSc MD, VP Officer | ||
| Lauren MBA, Senior Officer | ||
| Renee Lentini, VP Officer | ||
| Stacy Coen, Sr Officer | ||
| Audrey Bergan, Senior Officer | ||
| Courtney OKonek, Senior Relations | ||
| Isabel Kalofonos, Senior Officer | ||
| Anabel Chan, Head Relations | ||
| FACP MD, VP Affairs | ||
| Mark Enyedy, President CEO, Director | ||
| Theresa Wingrove, Vice President - Regulatory Affairs and Quality | ||
| Stacy MBA, Senior Officer |
ImmunoGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ImmunoGen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | |||
| Return On Asset | -0.0849 | |||
| Profit Margin | (0.26) % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 8.2 B | |||
| Shares Outstanding | 279.35 M | |||
| Shares Owned By Insiders | 0.32 % | |||
| Shares Owned By Institutions | 91.29 % | |||
| Number Of Shares Shorted | 20.61 M | |||
| Price To Earning | (4.49) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ImmunoGen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ImmunoGen's short interest history, or implied volatility extrapolated from ImmunoGen options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the ImmunoGen information on this page should be used as a complementary analysis to other ImmunoGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |